THERAPY DOSSIER · th-21c49ce06838

Anatabine

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: TBI
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 3

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT01551498 ↗PHASE2completed

Anatabloc (anatabine) on Antithyroid Autoantibodies and Thyroid Function in Autoimmune Thyroiditis

Thyroiditis, Autoimmune

Enrolment: 165 · Results not recorded

NCT01669876 ↗PHASE2terminated

Anatabloc (anatabine) in Subjects With Alzheimer's Disease

Alzheimer Disease

Enrolment: 85 · Results not recorded

NCT01740934 ↗NAcompleted

Anatabloc Creme (anatabine) in Subjects With Rosacea

Rosacea

Enrolment: 117 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 27889957 ↗2017Reported benefit

Acute or Delayed Treatment with Anatabine Improves Spatial Memory and Reduces Pathological Sequelae at Late Time-Points after Repetitive Mild Traumatic Brain Injury.

MouseTBIClosed-head / concussionC57BL/6 (per indexing terms)Male (per indexing terms)Oral, delivered continuously in drinking waterTreatment started 30 min after injury; a delayed arm was created by crossover a…

Model: Repetitive mild traumatic brain injury: five midline impacts at 5 m/s, 1 mm strike depth, 200 ms dwell time, at 48 h intervals

Both early and delayed anatabine treatment improved spatial memory and reduced astroglial and microglial responses at late time points after repetitive mild traumatic brain injury.

Extraction: extract · Subtype source: review · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…